Liquidia Corporation (LQDA)

NASDAQ: LQDA · IEX Real-Time Price · USD
7.13
+0.12 (1.71%)
At close: Feb 3, 2023, 4:00 PM
7.20
+0.07 (0.98%)
After-hours: Feb 3, 2023, 6:47 PM EST
1.71%
Market Cap 459.85M
Revenue (ttm) 13.79M
Net Income (ttm) -46.05M
Shares Out 64.50M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 625,229
Open 7.13
Previous Close 7.01
Day's Range 7.06 - 7.37
52-Week Range 3.26 - 8.79
Beta 0.13
Analysts Buy
Price Target 13.41 (+88.08%)
Earnings Date Mar 16, 2023

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2018
Employees 52
Stock Exchange NASDAQ
Ticker Symbol LQDA
Full Company Profile

Financial Performance

In 2021, Liquidia's revenue was $12.85 million, an increase of 1637.81% compared to the previous year's $739,628. Losses were -$34.58 million, -42.14% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is $13.41, which is an increase of 88.08% from the latest price.

Price Target
$13.41
(88.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?

Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe...

2 days ago - Zacks Investment Research

Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)

MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the PTAB has reaffirmed its original decision in the ‘793 IPR, which f...

2 days ago - GlobeNewsWire

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia...

3 days ago - GlobeNewsWire

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered into a Revenue Interest Financing Agreement with ...

3 weeks ago - GlobeNewsWire

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today a collaboration with Sandoz Inc. (Sandoz) and Mainbridge Health Partn...

2 months ago - GlobeNewsWire

Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 153.2% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is que...

2 months ago - Zacks Investment Research

Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?

Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

3 months ago - Zacks Investment Research

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company to host webcast and conference call today at 8:30 a.m. ET Company to host webcast and conference call today at 8:30 a.m. ET

3 months ago - GlobeNewsWire

ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS

The New Board Members Will Bring Industry Experience to Contribute to Company Growth WOODINVILLE, Wash. , Nov. 2, 2022 /PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology c...

Other symbols: CYAN
3 months ago - PRNewsWire

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The ...

3 months ago - GlobeNewsWire

Precedential Opinion Panel Denies United Therapeutics' Request for Review of ‘793 Inter Partes Review Decision

MORRISVILLE, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022, the Precedential Opinion Panel (POP) of the United States Patent and ...

3 months ago - GlobeNewsWire

Liquidia Announces Presentations at the CHEST 2022 Annual Meeting

MORRISVILLE, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YU...

3 months ago - GlobeNewsWire

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN) stock, a biotech firm working on a promising Alzheimer's therapy.

4 months ago - InvestorPlace

7 Momentum Stocks to Buy Now for Extraordinary Gains

Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement o...

4 months ago - InvestorPlace

Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.

MORRISVILLE, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United...

5 months ago - GlobeNewsWire

Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?

Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade

The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr...

5 months ago - Zacks Investment Research

Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen

We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.

Other symbols: STKL
5 months ago - Zacks Investment Research

Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy

Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is ques...

6 months ago - Zacks Investment Research

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st...

6 months ago - Zacks Investment Research

Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022. The ...

6 months ago - GlobeNewsWire

Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022

MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The...

6 months ago - GlobeNewsWire

Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation

MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA™ (trepros...

6 months ago - GlobeNewsWire